产品
编 号：F618310
分子式：C19H23N7Se2
分子量：507.35
分子式：C19H23N7Se2
分子量：507.35
产品类型
规格
价格
是否有货
结构图
CAS No: 2403650-93-9
产品详情
生物活性：
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
体内研究：
SLLN-15 (30mg/kg, PO, 3 times a week) not only inhibits the growth of TNBC in animal model, but also TNBC cell progression to metastases.Overall, oral SLLN-15 reveals a potent anticancer and anti-metastatic activity in mice bearing TNBC.Animal Model:BALB/c mice or SCID mice transplanted with mouse mammary carcinoma 4T1 cells and human breast adenocarcinoma MDA-MB-231 cells (1 X 106 cells/ each mouse)
Dosage:30mg/kg.
Administration:PO, 3 times a week for 40 days.
Result:Tumor allografts grew at a slower rate compared to control groups.Significant inhibition of the number of lung metastases as visualized.
体外研究：
SLLN-15 (0, 1, 5, 10, 25 μM) treatment for 24 h markedly decreases overall cell viability of breast cancer cells in a dose-dependent manner.SLLN-15 (100 nM and 1000 nM, 7 days) is able to equally inhibit the colony formation abilities of several breast cancer cell lines.Overall, SLLN-15 induces a dose-dependent anti-proliferative activity in the TNBC cell lines MDA-MB-231 and BT-20 via induction of autophagy and autophagic flux. This induction is associated with a selective inhibition of AKT-MTOR signaling.
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
体内研究：
SLLN-15 (30mg/kg, PO, 3 times a week) not only inhibits the growth of TNBC in animal model, but also TNBC cell progression to metastases.Overall, oral SLLN-15 reveals a potent anticancer and anti-metastatic activity in mice bearing TNBC.Animal Model:BALB/c mice or SCID mice transplanted with mouse mammary carcinoma 4T1 cells and human breast adenocarcinoma MDA-MB-231 cells (1 X 106 cells/ each mouse)
Dosage:30mg/kg.
Administration:PO, 3 times a week for 40 days.
Result:Tumor allografts grew at a slower rate compared to control groups.Significant inhibition of the number of lung metastases as visualized.
体外研究：
SLLN-15 (0, 1, 5, 10, 25 μM) treatment for 24 h markedly decreases overall cell viability of breast cancer cells in a dose-dependent manner.SLLN-15 (100 nM and 1000 nM, 7 days) is able to equally inhibit the colony formation abilities of several breast cancer cell lines.Overall, SLLN-15 induces a dose-dependent anti-proliferative activity in the TNBC cell lines MDA-MB-231 and BT-20 via induction of autophagy and autophagic flux. This induction is associated with a selective inhibition of AKT-MTOR signaling.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备